Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$67.87
-0.2%
$73.29
$61.24
$87.68
$210.48B0.495.25 million shs5.89 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$105.68
-0.8%
$108.48
$62.07
$119.96
$131.59B0.327.50 million shs7.57 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$8.00
+4.2%
$9.58
$6.50
$18.98
$841.53M1.54780,770 shs1.17 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
+2.59%+3.37%-12.36%+4.04%-1.33%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+2.77%+0.93%-4.43%+17.03%+56.46%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-5.13%+5.43%-17.92%-44.38%-53.74%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.3403 of 5 stars
3.55.01.70.02.70.01.3
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.5397 of 5 stars
2.44.01.74.14.12.51.9
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.4548 of 5 stars
3.51.00.00.03.24.20.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.09
Buy$86.8027.89% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.72
Moderate Buy$105.12-0.53% Downside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
3.00
Buy$30.25277.94% Upside

Current Analyst Ratings Breakdown

Latest GILD, RCUS, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
3/27/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$120.00 ➝ $130.00
3/11/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$123.00 ➝ $130.00
3/5/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$116.00 ➝ $126.00
3/5/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$120.00 ➝ $140.00
3/4/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$115.00 ➝ $132.00
2/26/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$18.00 ➝ $24.00
2/19/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$22.00 ➝ $17.00
2/18/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$80.00 ➝ $120.00
2/18/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$36.00 ➝ $25.00
2/18/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $18.00
(Data available from 4/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B3.89$5.76 per share11.79$13.18 per share5.15
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B4.58$8.35 per share12.66$15.44 per share6.84
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$258M3.26N/AN/A$6.17 per share1.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.2630.0313.571.4213.01%32.23%12.31%4/29/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$0.37285.6213.030.711.67%31.63%10.38%4/24/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$307M-$3.10N/AN/AN/A-102.66%-45.59%-22.38%5/6/2025 (Estimated)

Latest GILD, RCUS, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10N/AN/AN/A$13.71 billionN/A
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.73N/AN/AN/A$6.77 billionN/A
2/25/2025Q4 2024
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.17-$1.03+$0.14-$1.03$29.38 million$36.00 million
2/11/2025Q4 2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.67$1.90+$0.23$1.42$7.15 billionN/A
2/6/2025Q4 2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.05-$0.05$0.48$14.19 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.063.04%+1.98%91.15%N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.99%+2.74%854.05%N/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A

Latest GILD, RCUS, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%3/14/20253/14/20253/28/2025
2/6/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$1.032%2/21/20252/21/20253/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.93
0.74
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.24
1.50
1.20
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.08
5.24
5.24

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
12.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
83,5003.10 billionN/AOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.25 billion1.24 billionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500105.14 million80.26 millionOptionable

Recent News About These Companies

Precision BioSciences reports Q4 EPS ($2.22), consensus ($2.94)
Arcus Biosciences management to meet with Cantor Fitzgerald

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$67.87 -0.14 (-0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$68.00 +0.13 (+0.19%)
As of 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$105.68 -0.82 (-0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$105.93 +0.25 (+0.24%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$8.00 +0.32 (+4.22%)
Closing price 03:59 PM Eastern
Extended Trading
$7.84 -0.16 (-2.05%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.